Editas Medicine Inc (NAS:EDIT)
$ 1.199 -0.011 (-0.91%) Market Cap: 99.88 Mil Enterprise Value: -126.72 Mil PE Ratio: 0 PB Ratio: 0.57 GF Score: 46/100

Editas Medicine Inc at Barclays Gene Editing & Gene Therapy Summit (Virtual) Transcript

Nov 15, 2021 / 01:30PM GMT
Release Date Price: $35.99 (-5.04%)
Gena Wang
Barclays Capital - Analyst

Thank you, everyone. Welcome to our next presenting company. It is my great pleasure to introduce our next presenting company, Editas Medicine. With us, we have Lisa Michaels, Chief Medical Officer; we also have Mark Shearman, Chief Scientific Officer, with us. Lisa, Mark do you want to give a quick overview on Editas? And then we can dive into the questions.

Lisa Michaels
Editas Medicine, Inc. - EVP and CMO

No, Gena. It's wonderful to have an opportunity to talk to you and with everyone else today. I am just letting you know, this is the end of my first full year at Editas, and it has been an exciting road so far to date. My real pleasure over the last year has been really getting the clinical programs moving forward and getting momentum in patient enrollment across all our various programs and portfolio.

Over the last year, some of the main achievements that we have gotten is the BRILLIANCE study in Leber's congenital amaurosis type 10, moving forward relatively aggressively and had the first time that Editas

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot